In long-term studies, people who came off semaglutide regained about two-thirds of the weight they had lost within a year, and many saw blood sugar, cholesterol, and blood pressure trend back toward where they started
Reported Issues: Consumers report: That the supplement did not lead to weight loss or appetite suppression as advertised That the product was marketed using misleading claims about GLP-1 support That they paid for a product that did not provide the promised benefits That the supplements are promoted as alternatives to GLP-1 medications, despite not functioning like prescription GLP-1 drugs That marketing materials imply that these supplements are scientifically and medically proven and reliable, when evidence may be lacking That they would not have purchased the supplements if they had known the claims were not supported by reliable scientific evidence Experiencing adverse side effects such as stomach pain, nausea, or weight gain Why Individuals Should Be Concerned: Potential claims include: Economic loss Safety risk False advertising Product defect Performance vs
Team Coordination Surgical, anesthetic, and endocrine teams need to coordinate if surgery is planned after semaglutide is stopped
So what is going on mechanistically
Not strictly
Section 1886(d)(4)(C)(i) of the Act states that the Secretary shall adjust the weighting factors at least annually to reflect changes in treatment patterns, technology, and other factors which may change the relative use of hospital resources
